An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

July 2, 2020

Study Completion Date

July 2, 2020

Conditions
MelanomaSkin Cancer
Interventions
DRUG

BMS-986205

specified dose on specified day

BIOLOGICAL

Nivolumab

Specified dose on specified day

DRUG

Placebo

Specified dose on specified day

Trial Locations (63)

4

Local Institution, Dublin

7

Local Institution, Dublin

2146

Melanoma Institute Australia, North Sydney

2148

Local Institution, Blacktown

3000

Local Institution, Melbourne

3004

Local Institution, Melbourne

3128

Local Institution, Box Hill

4120

Local Institution, Greenslopes

Local Institution, Woolloongabba

6021

Local Institution, Wellington

8091

Universitaetsspital Zuerich, Zurich

15706

Local Institution, Santiago Compostela

20133

Local Institution, Milan

21614

Elbe Klinikum Buxtehude, Buxtehude

23007

Local Institution, Jaén

28007

Local Institution, Madrid

29010

Local Institution, Málaga

30625

Local Institution, Hanover

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

37075

Georg August Universitaet Goettingen, Göttingen

42055

Local Institution, Saint-Etienne

45147

Local Institution, Essen

46026

Local Institution, Valencia

53100

Azienda Ospedaliera Universitaria Senese, Siena

57001

Interbalkan European Medical Center, Thessaloniki

60637

University Of Chicago, Chicago

69120

Local Institution, Heidelberg

72076

Local Institution, Tübingen

80045

University Of Colorado, Aurora

80131

Istituto Nazionale Tumori Fondazione Pascale, Napoli

80337

Local Institution, München

90025

Angeles Clinic and Research Institute, Los Angeles

92104

Local Institution, Boulogne-Billancourt

94805

Local Institution, Villejuif

97239

Oregon Health & Science University, Portland

98109

Local Institution, Seattle

1040045

Local Institution, Chuo-ku

5418567

Local Institution, Osaka

7000914

Local Institution, Okayama

9518566

Local Institution, Niigata

9808574

Local Institution, Sendai

H3T 1E2

Local Institution, Montreal

G1R 2J6

Local Institution, Québec

500 05

Klinika onkologie a radioterapie, Hradec Králové

100 34

Dermatovenerologicka klinika 3. LF UK a FNKV, Prague

128 08

Dermatovenerologicka klinika VFN a 1. LF UK, Prague

01307

Universitaetsklinikum Carl Gustav Carus, Dresden

Unknown

SRH Wald-Kliniken Gera GmbH, Gera

Local Institution, Dooradoyle

Local Institution, Christchurch

1066 CX

Local Institution, Amsterdam

9700RB

Local Institution, Groningen

6525 GA

Local Institution, Nijmegen

3008 AE

Local Institution, Rotterdam

02-781

Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warsaw

08036

Local Institution, Barcelona

SW17 0RE

Local Institution, London

SW3 6JJ

Local Institution, London

BT9 7AB

Local Institution, Belfast

CB2 0QQ

Local Institution, Cambridge

HU16 5JQ

Local Institution, Cottingham

M20 4BX

Local Institution, Manchester

TA1 5DA

Local Institution, Tauton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY